|Heather Baudet, MD, PhD||Executive Leadership|
|Rong Mao, MD||Executive Leadership|
|Stephanie Crowley, PhD||Executive Committee|
|Gregory Enns, MD||Executive Committee|
|Annette Feigenbaum, MD||Executive Committee|
|Jenny Goldstein, PhD, CGC||Executive Committee|
|C. Lisa Kurtz, PhD||Executive Committee|
|Elaine Lyon, PhD||Executive Committee|
|Jennifer McGlaughon, PhD||Executive Committee|
|Marzia Pasquali, PhD||Executive Committee|
|Kathleen Wallace, BSc (Hons)||Executive Committee|
|Ozlem Senol||Executive Committee|
|Meredith Weaver PhD, ScM, CGC||Coordinator|
Please contact a coordinator if you have questions.
A systematic process of evaluating evidence to classify a genomic variant on a spectrum from pathogenic to benign with respect to a particular disease and inheritance pattern.